SBFM, esta es para 2016, ya que no prevén el inicio de Fase I hasta entonces....
La tengo aparte, para dejarla y no tocarla, a ver si en un año o dos la vendo bien vendida....
Han firmado contrato con LONZA (laboratorio Suizo) para la fabricación de 2Kg de compuesto, de cara a los ensayos de Fase I...
La última new que han publicado es que LONZA les ha mandado unas muestras para que verifiquen que están correctas...
Se trata de un producto, el Adva27, que según un artículo de 2012 publicado en la revista Anti Cáncer Journal Rsearch, sería bastante prometedor, en varios tipos de cáncer, ya que inhibiría el Top2 o topoisomerasa 2...
Son 2 los genes asociados con formas agresivas de cáncer: HER2 y TOP2. Herceptin (Roche) es un tratamiento efectivo para pacientes positivos en HER2. Para pacientes positivos en TOP2, creo que no existen terapias efectivas a día de hoy. Las ventas de Herceptín son de 1,8 billones al año.
TOP2 condifica la Topoisomerasa II, un enzima que desarrolla ADN y es necesario para la proliferación celular. HER2 y TOP2 se situan en el cromosoma 17. Al menos 10 variantes de TOP2 se han encontrado en células de cáncer de pecho.
La inhibición de la actividad de la Topoisomerasa II es esencial para luchar en cánceres agresivos, incluído el de pecho.
Los datos publicados muestran que ADVA-27 es un inhibidor de la Topoisomerasa II más efectivo a la hora de destruir cánceres agresivos que ETOPOSIDE, la droga actualmente usada.
SBFM
En relacion al ébola, os pego una new de noviembre de 2014...
Montreal, Quebec, Canada -- (MARKETWIRE) -- Sunshine Biopharma Inc. (OTCQB: SBFM), a
pharmaceutical company focused on the research, development and commercialization of drugs
for the treatment of various forms of cancer, today announced that it has conducted a scientific
review of the mechanisms by which Ebola virus penetrates human cells and takes over their
machinery to multiply rapidly and go on to infecting other cells leading to massive cell
destruction and ultimately death in nearly 80% of the cases. The review found that the
progression of Ebola virus infection is very similar to that of Influenza A virus, the causative
agent that was responsible for the death of over 90 million people in the 1918 flu pandemic. In
severe Influenza A virus infections, a condition associated with high mortality rate called
haemophagocytic lymphohistiocytosis (HLH) is developed by the affected patient. HLH has
previously been treated successfully with Etoposide which increased survivability from 50% to
90% (LANCET, Volume 367, Pages 870-873, March 2006). Etoposide is an anticancer drug
that inhibits the activity Topoisomerase II, an essential enzyme found in hyperactive, rapidly
growing cells such as cancer cells and HLH cells. Like Etoposide, Sunshine Biopharma’s lead
anticancer compound, Adva-27a, is a Topoisomerase II inhibitor however it has been shown to
be more effective and less toxic than Etoposide (ANTICANCER RESEARCH, Volume 32,
Pages 4423-4432, October 2012). The latter characteristics make Adva-27a superior to
Etoposide for possible treatment of Ebola patients with already weakened state of health.
..........................................................................................................
Sacado del último 10Q....
● Adva-27a is effective at killing different types of multidrug resistant cancer cells, including:
o Breast Cancer Cells (MCF-7/MDR)
o Small Cell Lung Cancer Cells (H69AR)
o Uterine Cancer (MES-SA/Dx5)
o Pancreatic Cancer (Panc-1)
● Adva-27a is unaffected by P-Glycoprotein, the enzyme responsible for making cancer cells resistant to anti-tumor drugs.
● Adva-27a has excellent clearance time (half-life = 54 minutes) as indicated by human microsomes stability studies and pharmacokinetics data in rats.
● Adva-27a clearance is independent of Cytochrome P450, a mechanism that is less likely to produce toxic intermediates.
●
Adva-27a is an excellent inhibitor of Topoisomerase II with an IC50 of only 13.7 micromolar (this number has recently been reduce to 1.44 micromolar as a
result of resolving the two isomeric forms of Adva-27a).
● Adva-27a has shown excellent pharmacokinetics profile as indicated by studies done in rats.
● Adva-27a does not inhibit tubulin assembly
